Jack Pace | White & Case LLP International Law Firm, Global Law Practice
Jack Pace
Jack Pace

Jack Pace

Partner, New York

In 2013, Law360 recognized Jack Pace as one of five “Rising Stars” under 40 in US competition law.


Jack Pace is one of the driving forces in White & Case's leading global antitrust litigation practice. He has earned a reputation for creative solutions in high stakes matters. He is also the Executive Partner of the Firm's New York Office.

Jack has achieved several major victories for his clients in complex litigation matters, including jury verdicts (Fair Isaac v. Experian), dismissals of antitrust claims on the pleadings and at summary judgment (Doryx "product hopping" litigation, Loestrin "reverse payment" litigation, White v. JP Morgan Chase; VantageScore antitrust litigation), and groundbreaking defeats of class certification (Blades v. Monsanto).

Jack is currently representing several leading global pharmaceutical companies (including Pfizer, Boehringer Ingelheim, and Allergan/Actavis) in class action litigation matters at the cutting edge of antitrust and intellectual property.

He has been recognized as a leading antitrust lawyer by several publications, was named a "Rising Star under age 40" among US competition lawyers by Law360 in 2013, a "Rising Star" among all New York lawyers by the New York Law Journal in 2013, and a competition law "MVP" by Law360 in 2011.

Jack works with clients across a broad spectrum of industries, including pharmaceuticals, financial services, agriculture, energy, and insurance.

He has made major contributions to the Firm's pro bono clients, in cases involving areas such as domestic violence, criminal appeals, and special education. He is also the Chair of the Board of Reach Out and Read of Greater New York, a not-for-profit organization focused on school readiness and early literacy.

Jack regularly speaks and writes on antitrust, attorney-client privilege, e-discovery, and other complex litigation topics. He is an associate editor of Antitrust Magazine and regularly contributes articles on antitrust law, class certification, and other complex commercial litigation topics.

Bars and Courts

  • New York State Bar
  • US District Court for the Southern District of New York
  • US District Court for the Eastern District of New York
  • US Court of Appeals for the Second Circuit
  • US Court of Appeals for the Third Circuit
  • US Court of Appeals for the Fifth Circuit
  • US Court of Appeals for the Seventh Circuit
  • US Court of Appeals for the Eighth Circuit


  • JD, Fordham University School of Law, Cum laude, Stein Scholar, Order of the Coif
  • BA, Fordham University, Summa cum laude, Phi Beta Kappa


  • English
Download Full Bio


Antitrust and innovation

Represented Warner Chilcott/Actavis in litigation brought by competitor Mylan, challenging Warner Chilcott's transition to new versions of its Doryx acne treatment. Jack and the White & Case team obtained dismissal of all of Plaintiff's claims on summary judgment, representing the first summary judgment dismissal of so-called pharmaceutical "product hopping" claims in the United States.

Antitrust challenges to pharmaceutical settlement agreements

National trial counsel for several leading innovator pharmaceutical manufacturers (including Actavis, Allergan, Boehringer Ingelheim, Pfizer, and Warner Chilcott) in antitrust challenges to settlement agreements and other business arrangements between innovators and generic manufacturers. Among other things, Jack is playing a leading role in the class certification and economic analyses involved in these cases.

Consolidated price-fixing class actions

Successfully defended a leading global potash supplier in consolidated class action litigation involving claims under antitrust and unfair competition laws.

FDA regulatory approval of innovative pharmaceutical products

Successfully defended a leading global pharmaceutical manufacturer in preliminary injunction proceedings that challenged Food and Drug Administration (FDA) approval of a complex drug based on biological material.

Experian Information Solutions, Inc.

Representing Experian, Jack and his colleagues obtained a jury verdict on all claims brought by Fair Isaac Corporation in an action concerning allegations of unfair competition and trademark infringement in the sale of credit risk scoring services. The jury also found in favor of Experian on its counterclaim that the plaintiff had committed fraud on the US Patent and Trademark Office in obtaining its registration for the trademark-in-suit. Jack and his colleagues also obtained dismissal of all antitrust and false advertising claims on summary judgment. The trial victory and summary judgment victory were upheld by the 8th Circuit Court of Appeals.

Experian Information Solutions, Inc.

Representing Experian, Jack and his colleagues obtained dismissal of all claims in a nationwide class action asserting antitrust claims against leading financial institutions, credit reporting companies, and credit scoring agencies.

Defense against deceptive and unfair trade practice claims

Jack represented a legal services support company in class action litigation asserting claims under state deceptive and unfair trade practice laws. Jack and his colleagues obtained denial of the class certification motion and dismissal of all claims against our client.

Additional examples of Jack's representative matters are available upon request.

Speaking Engagements

Recent Antitrust Developments: June, July and August 2013, ABA Section of Antitrust Law, Health Care and Pharmaceuticals Committee, September 13, 2013

Class Actions in Federal Court after Shady Grove, sponsored by Strafford Publications Inc., July 14, 2011

US Supreme Court's Decision in AT&T Mobility, LLC v. Concepcion, Bloomberg Radio, April 28, 2011

Guest Lecturer in Antitrust Law, Fordham University School of Law, 2009, 2010, and 2012

A complete list of Jack's presentations and public addresses is available upon request.


  • Third Circuit Holds, 'Give Peace a Chance': The De Beers Litigation and the Potential Power of Settlement, Antitrust, Volume 27, No. 2, Spring 2013, (co-author)
  • E-discovery 'Worst Practices', The Senior Lawyer 1, 56, Spring 2012, (co-author)
  • Antitrust Law Developments (Seventh), 2012, (contributor to chapter on equitable and class action tolling)
  • The Monopolization and Dominance Handbook, American Bar Association, Antitrust Section, July 2011, (contributing editor)
  • From Shady to Dark: One Year Later, Shady Grove's Meaning Remains Unclear, Antitrust, Volume 25, No. 2, Spring 2011, (co-author)
  • E-discovery 'Worst Practices': Ten Sure-Fire Ways to Mismanage Document Review and Production, 14 N.Y. Bus. L.J. 2, 62, Winter 2010, (co-author)
  • E-discovery 'Worst Practices', 2 The Senior Lawyer 2, 33, Fall 2010, (co-author)
  • E-discovery 'Worst Practices': Ten Sure-Fire Ways to Mismanage a Litigation Hold, 13 N.Y. Bus. L.J. 2, 48, Fall 2009, (co-author)
  • Conspiratologists at the Gate: The Scope of Expert Testimony on the Subject of Conspiracy in a Sherman Act Case, Antitrust, Volume 17, No. 2, Spring 2003, (co-author)
  • A complete list of Jack's publications is available upon request.

Awards & Recognition

MVP, Life Sciences, Law360, 2015

Co-MVP, Antitrust Litigation – Competition, Law 360, 2011

Named to Best Lawyers in America (22nd edition) for Antitrust Law, 2015

New York City Bar's Antitrust & Trade Regulation Committee, 2014, 2015

Rising Star, US Competition Lawyers aged 40 and under, Law 360, 2013

Rising Star aged 40 and under, New York Law Journal, 2013